Pacific Bio (PACB) Reports In-Line Q4 EPS

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $26.59 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Cerebras Q1 EPS miss sends shares down 9% after-hours